Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate

This study has been completed.
Information provided by (Responsible Party):
Takeda Identifier:
First received: April 27, 2009
Last updated: May 23, 2012
Last verified: May 2012
The purpose of this study is to examine the genetic contribution to the mechanism of lapaquistat acetate- induced hepatic abnormalities.

Condition Intervention
Other: Pharmacogenomic whole blood sampling

Study Type: Observational
Study Design: Observational Model: Case Control
Official Title: A Modified Case Control Study to Identify Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate

Further study details as provided by Takeda:

Primary Outcome Measures:
  • Whole genome scanning using the Illumina 1M chip. [ Time Frame: Visit 2 ]
  • Whole genome scanning using the Affymetrix 500K array chip. [ Time Frame: Visit 2 ]
  • Candidate gene scanning using the Affymetrix Drug Metabolizing Enzymes and Transporter (DMET) array. [ Time Frame: Visit 2 ]

Biospecimen Retention:   Samples With DNA
Pharmacogenomic whole blood sample

Estimated Enrollment: 66
Study Start Date: May 2009
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Lapaquistat acetate participants Other: Pharmacogenomic whole blood sampling
10 mL, whole blood, one sample on Visit 2
Other Name: TAK-475

Detailed Description:

This is a modified case control study to investigate the association of genotype with phenotype in subjects who experienced alanine aminotransferase and bilirubin derangements following exposure to lapaquistat acetate.

The DNA profile of subjects who experienced significant biochemical hepatic derangement following exposure to lapaquistat acetate (cases) will be compared with a population of pre-genotyped untreated individuals (controls) from a public database. The DNA from subjects who had hepatic derangement during lapaquistat acetate studies, in the absence of exposure to lapaquistat acetate, will be stored. If data from the subjects exposed to lapaquistat acetate indicates that there is a genetic marker of interest, the stored DNA from non-exposed subjects will be assayed to further investigate the signal. One 10 mL sample of whole blood will be collected in plastic K2EDTA tube, after informed consent has been obtained.

Each subject will sign the informed consent document prior to undergoing the study-related procedure. One 10 mL sample of whole blood will be collected from each subject. Extracted DNA will be analyzed using a whole genome scan approach as well as a candidate gene approach.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects who participated in lapaquistat acetate phase 2 and phase 3 clinical studies

Inclusion Criteria:

  • Has experienced an alanine aminotransferase level greater than or equal to 5 times the upper limit of normal, or concurrent elevation of alanine aminotransferase greater than or equal to 3 times the upper limit of normal and bilirubin greater than or equal to 2 times the upper limit of normal while participating in lapaquistat acetate clinical studies.

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00890448

  Show 19 Study Locations
Sponsors and Collaborators
Study Director: Medical Director Takeda
  More Information

Responsible Party: Takeda Identifier: NCT00890448     History of Changes
Other Study ID Numbers: TAK-475_310
2008-006906-41 ( Registry Identifier: EudraCT )
U1111-1112-3768 ( Registry Identifier: WHO )
DOH-27-0410-2857 ( Registry Identifier: SANCTR )
Study First Received: April 27, 2009
Last Updated: May 23, 2012

Keywords provided by Takeda:
Alanine Transaminase elevation
Genetic Markers
DNA Markers processed this record on April 28, 2017